Cargando…

Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma

BACKGROUND: This study aimed to evaluate the value of combining the nodal maximal standard uptake values (SUVmax) of (18) F-fluoro-2-deoxy-D-glucose positron emission tomography with Epstein-Barr virus DNA(EBV DNA) levels to predict distant metastasis for nasopharyngeal carcinoma (NPC) patients PATI...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wen-Hui, Tang, Lin-Quan, Zhang, Lu, Chen, Qiu-Yan, Guo, Shan-Shan, Liu, Li-Ting, Fan, Wei, Zhang, Xu, Guo, Ling, Zhao, Chong, Cao, Ka-Jia, Qian, Chao-Nan, Guo, Xiang, Xie, Dan, Zeng, Mu-Sheng, Mai, Hai-Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742000/
https://www.ncbi.nlm.nih.gov/pubmed/26512922
Descripción
Sumario:BACKGROUND: This study aimed to evaluate the value of combining the nodal maximal standard uptake values (SUVmax) of (18) F-fluoro-2-deoxy-D-glucose positron emission tomography with Epstein-Barr virus DNA(EBV DNA) levels to predict distant metastasis for nasopharyngeal carcinoma (NPC) patients PATIENTS AND METHODS: Eight hundred seventy-four patients with stage III-IVa-b NPC were evaluated for the effects of combining SUVmax and EBV DNA levels on distant metastasis-free survival (DMFS), disease-free survival (DFS) and overall survival (OS). RESULTS: The optimal cutoff value was 6,220 copies/mL for EBV DNA and 7.5 for SUVmax-N. Patients with lower EBV DNA levels or SUVmax-N had a significantly better 3-year DMFS, DFS, and OS. Patients were divided into four groups based on EBV DNA and SUVmax-N, as follows: low EBV DNA and low SUVmax-N (LL), low EBV DNA and high SUVmax-N (LH), high EBV DNA and low SUVmax-N (HL), and high EBV DNA and high SUVmax-N (HH). There were significant differences between the four mentioned groups in 3-year DMFS: 95.7%, 92.2%, 92.3%, and 80.1%, respectively (P(trend) < 0.001). When looking at the disease stage, the 3-year DMFS in group LL, LH, HL, HH were 94.2%, 92.9%, 95.0%, and 81.1%, respectively, in stage III patients (P(trend) < 0.001) and 92.7%, 87.2%, 86.3%, and 77.0% in stage IVa–b patients (P(trend) = 0.026). CONCLUSION: Pretreatment EBV DNA and SUVmax of neck lymph nodes were independent prognostic factors for distant metastasis in NPC patients. Combining EBV DNA and SUVmax-N led to an improved risk stratification for distant metastasis in advanced-stage disease.